['neovascular age-related macular degeneration']
['gb-102', 'aflibercept']

        Key Inclusion Criteria:

          1. Males or females of any race, ≥ 50 years of age

          2. Presence of an active CNV lesion secondary to AMD treated with at least 3 monthly
             injections of an anti-VEGF agent (aflibercept, bevacizumab, or ranibizumab)

          3. Evidence of increased vascular permeability and/or loss of visual acuity

        Key Exclusion Criteria:

          1. History, within 6 months prior to screening, of any of the following: myocardial
             infarction, any cardiac event requiring hospitalization, treatment for acute
             congestive heart failure, transient ischemic attack, or stroke

          2. Uncontrolled hypertension, diabetes mellitus, IOP, hypothyroidism, or hyperthyroidism

          3. Chronic renal disease

          4. Abnormal liver function

          5. Women who are pregnant or lactating
      